These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Lafrance JP; Miller DR Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):923-31. PubMed ID: 19585463 [TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis. Ungprasert P; Srivali N; Kittanamongkolchai W Eur J Intern Med; 2015 Nov; 26(9):685-90. PubMed ID: 26427540 [TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. Ungprasert P; Srivali N; Thongprayoon C Clin Cardiol; 2016 Feb; 39(2):111-8. PubMed ID: 26720629 [TBL] [Abstract][Full Text] [Related]
7. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. McGettigan P; Henry D JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831 [TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rahme E; Nedjar H Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138 [TBL] [Abstract][Full Text] [Related]
10. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Lee T; Lu N; Felson DT; Choi HK; Dalal DS; Zhang Y; Dubreuil M Rheumatology (Oxford); 2016 Jun; 55(6):1099-105. PubMed ID: 26983451 [TBL] [Abstract][Full Text] [Related]
11. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Valat JP; Deray G; Héloire F Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592 [TBL] [Abstract][Full Text] [Related]
12. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. Bally M; Dendukuri N; Rich B; Nadeau L; Helin-Salmivaara A; Garbe E; Brophy JM BMJ; 2017 May; 357():j1909. PubMed ID: 28487435 [No Abstract] [Full Text] [Related]
13. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Jaturapatporn D; Isaac MG; McCleery J; Tabet N Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD006378. PubMed ID: 22336816 [TBL] [Abstract][Full Text] [Related]
14. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Kearney PM; Baigent C; Godwin J; Halls H; Emberson JR; Patrono C BMJ; 2006 Jun; 332(7553):1302-8. PubMed ID: 16740558 [TBL] [Abstract][Full Text] [Related]
15. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336 [TBL] [Abstract][Full Text] [Related]
16. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Asghar W; Jamali F Inflammopharmacology; 2015 Feb; 23(1):1-16. PubMed ID: 25515365 [TBL] [Abstract][Full Text] [Related]
17. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Hernández-Díaz S; Varas-Lorenzo C; García Rodríguez LA Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):266-74. PubMed ID: 16611201 [TBL] [Abstract][Full Text] [Related]
18. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Chen LC; Ashcroft DM Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957 [TBL] [Abstract][Full Text] [Related]
19. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. Arfè A; Scotti L; Varas-Lorenzo C; Nicotra F; Zambon A; Kollhorst B; Schink T; Garbe E; Herings R; Straatman H; Schade R; Villa M; Lucchi S; Valkhoff V; Romio S; Thiessard F; Schuemie M; Pariente A; Sturkenboom M; Corrao G; BMJ; 2016 Sep; 354():i4857. PubMed ID: 27682515 [TBL] [Abstract][Full Text] [Related]
20. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac. Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]